Compare ATON & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATON | XAIR |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | British Virgin Islands | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 10.5M |
| IPO Year | N/A | N/A |
| Metric | ATON | XAIR |
|---|---|---|
| Price | $0.68 | $1.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 12.9M | ★ 22.1M |
| Earning Date | 02-27-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,802,000.00 |
| Revenue This Year | N/A | $127.85 |
| Revenue Next Year | N/A | $165.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $0.56 | $0.67 |
| 52 Week High | $15.82 | $10.40 |
| Indicator | ATON | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 57.11 |
| Support Level | N/A | $1.43 |
| Resistance Level | N/A | $2.26 |
| Average True Range (ATR) | 0.00 | 0.31 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 45.74 |
AlphaTON Capital Corp is a specialized digital asset treasury company focused on building and managing a strategic reserve of TON tokens and developing the Telegram ecosystem. The company implements a comprehensive treasury strategy that combines direct token acquisition, validator operations, and strategic ecosystem investments to generate sustainable returns for shareholders. Through its operations, it provides public market investors with institutional-grade exposure to the TON ecosystem and Telegram's billion user platform.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.